VERTEX PHARMACEUTICALS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 484.2 USD | -0.27% |
|
+6.27% | +18.93% |
Presenter SpeechPhilip Nadeau (Analysts)Good afternoon, and welcome once again to Cowen & Comp...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
11/06/2024
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5
USD
Average target price
463.5
USD
Spread / Average Target
-4.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.93% | 13TCr | |
| +14.51% | 11TCr | |
| -4.81% | 2.46TCr | |
| +3.23% | 2.28TCr | |
| -10.44% | 1.82TCr | |
| -41.74% | 1.65TCr | |
| -12.66% | 1.65TCr | |
| +2.44% | 1.34TCr | |
| +28.30% | 1.11TCr | |
| +81.55% | 921.73Cr |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated Presents at 42nd Annual Cowen Health Care Conference, Mar-08-2022 02
